ResearchMoz presents professional and in-depth study of "Metastatic Hormone Refractory Prostate Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025".
Cancer is one of the most fatal and chronic disorders, in which, there is development of tumor due to uncontrolled growth of cells in particular part of the body. Cancer is highly hazardous disease, in which, the mortality rate is extremely high, due to highly invasive nature and prolonged duration of disease.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1376064
Metastatic hormone refractory prostate cancer is the cancer of prostate glands. Prostate cancer is the most common form of cancer that affects men. In most of the cases, cancer remains confined to prostate gland, even after treatment. Hence, it is usually difficult and very painful to treat prostate cancer. The diagnostic tests may preliminary include deep study of patient’s history and reasons of pain. Afterwards, the diagnosis of metastatic hormone refractory prostate cancer is carried out by utilizing imaging studies, such as, CT scan, MRI, bone scanning, and PET scanning. Biopsy test is also used for diagnosis and confirmation of the disease. Moreover, rising level of prostate-specific antigens (PSA) in a patient treated with prostate cancer indicates that the disease has returned.
The market of metastatic hormone refractory prostate cancer is segmented on the basis of therapies and treatments available, such as, radiation therapy, chemotherapy, and cryosurgery. Radiation therapy mainly includes high energy X-rays or gamma-rays that are used to destroy the tumors. Hormone therapy is considered as the major therapy to treat metastatic hormone refractory prostate cancer. Major hormones used for the treatment of metastatic hormone refractory prostate cancer include goserelin (Zoladex), histrelin (Vantas), and leuprolide (Lupron) amongst others. Additionally, combined hormone therapy includes flutamide (Eulexin and others), nilutamide (Nilandron) and others. Chemotherapy is pharmacological treatment by using anti-cancer drugs either orally or parenterally. Major drugs used to treat this cancer include ketoconazole, dexamethasone, glucocorticoids, bisphosphonates, and finasteride (5-alpha reductase inhibitors) amongst others. Cryosurgery is also sometimes considered as the major therapy to treat metastatic hormone refractory prostate cancer. In addition, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The North American region is the most dominating market in the world, owing to rapidly growing incidences of prostate cancer and rising focus towards R&D to treat metastatic hormone refractory prostate cancer. On the other hand, Asia-Pacific and RoW are the most promising markets in the upcoming period, owing to rising awareness of prostate cancer, its chronic impact and treatments.
Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1376064
The market of metastatic hormone refractory prostate cancer is expected to steady growth rate during forecast period from 2014 – 2020. This growth is anticipated to be driven by various factors, such as, R&D practices running across the globe and high prevalence of prostate cancer. Owing to R&D practices, a number of drugs and formulations, such as, MDX-010 (Ipilimamab), MDV3100, Abiraterone and others are under pipeline studies and are expected to enter in the market during forecast period. Additionally, high prevalence of the disease is the major driver of the market growth. According to American Cancer Society estimates, approximately 233,000 new cases of prostate cancer are expected to diagnose in 2014, out of which, around 30,000 people may die due to prostate cancer. Hence, this high prevalence is the major driver of the market growth. In addition, rising awareness amongst the population for prostate cancer, and increasing medical infrastructure also support the growth of this market. However, high cost of R&D, diagnosis and treatment and lack of awareness in large number of countries (particularly belongs to Asia-Pacific and RoW region) are the major hurdles in the growth of this market.
The major players operating in this market include Novartis International AG, Pfizer, Inc., AstraZeneca plc, Genentech, Inc., Merck & Co, Inc. and Eli Lilly and Company amongst others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/metastatic-hormone-refractory-prostate-cancer-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Cancer is one of the most fatal and chronic disorders, in which, there is development of tumor due to uncontrolled growth of cells in particular part of the body. Cancer is highly hazardous disease, in which, the mortality rate is extremely high, due to highly invasive nature and prolonged duration of disease.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1376064
Metastatic hormone refractory prostate cancer is the cancer of prostate glands. Prostate cancer is the most common form of cancer that affects men. In most of the cases, cancer remains confined to prostate gland, even after treatment. Hence, it is usually difficult and very painful to treat prostate cancer. The diagnostic tests may preliminary include deep study of patient’s history and reasons of pain. Afterwards, the diagnosis of metastatic hormone refractory prostate cancer is carried out by utilizing imaging studies, such as, CT scan, MRI, bone scanning, and PET scanning. Biopsy test is also used for diagnosis and confirmation of the disease. Moreover, rising level of prostate-specific antigens (PSA) in a patient treated with prostate cancer indicates that the disease has returned.
The market of metastatic hormone refractory prostate cancer is segmented on the basis of therapies and treatments available, such as, radiation therapy, chemotherapy, and cryosurgery. Radiation therapy mainly includes high energy X-rays or gamma-rays that are used to destroy the tumors. Hormone therapy is considered as the major therapy to treat metastatic hormone refractory prostate cancer. Major hormones used for the treatment of metastatic hormone refractory prostate cancer include goserelin (Zoladex), histrelin (Vantas), and leuprolide (Lupron) amongst others. Additionally, combined hormone therapy includes flutamide (Eulexin and others), nilutamide (Nilandron) and others. Chemotherapy is pharmacological treatment by using anti-cancer drugs either orally or parenterally. Major drugs used to treat this cancer include ketoconazole, dexamethasone, glucocorticoids, bisphosphonates, and finasteride (5-alpha reductase inhibitors) amongst others. Cryosurgery is also sometimes considered as the major therapy to treat metastatic hormone refractory prostate cancer. In addition, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The North American region is the most dominating market in the world, owing to rapidly growing incidences of prostate cancer and rising focus towards R&D to treat metastatic hormone refractory prostate cancer. On the other hand, Asia-Pacific and RoW are the most promising markets in the upcoming period, owing to rising awareness of prostate cancer, its chronic impact and treatments.
Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1376064
The market of metastatic hormone refractory prostate cancer is expected to steady growth rate during forecast period from 2014 – 2020. This growth is anticipated to be driven by various factors, such as, R&D practices running across the globe and high prevalence of prostate cancer. Owing to R&D practices, a number of drugs and formulations, such as, MDX-010 (Ipilimamab), MDV3100, Abiraterone and others are under pipeline studies and are expected to enter in the market during forecast period. Additionally, high prevalence of the disease is the major driver of the market growth. According to American Cancer Society estimates, approximately 233,000 new cases of prostate cancer are expected to diagnose in 2014, out of which, around 30,000 people may die due to prostate cancer. Hence, this high prevalence is the major driver of the market growth. In addition, rising awareness amongst the population for prostate cancer, and increasing medical infrastructure also support the growth of this market. However, high cost of R&D, diagnosis and treatment and lack of awareness in large number of countries (particularly belongs to Asia-Pacific and RoW region) are the major hurdles in the growth of this market.
The major players operating in this market include Novartis International AG, Pfizer, Inc., AstraZeneca plc, Genentech, Inc., Merck & Co, Inc. and Eli Lilly and Company amongst others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/metastatic-hormone-refractory-prostate-cancer-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment